Zymeworks leverages Irish tax attributes in acquisition with Mylan
What happened
Zymeworks is integrating the acquisition of YUPELRI (revefenacin) into its commercial portfolio, which is related to COPD therapy. The company stated it expects total revenue for 2026, including collaboration revenue from YUPELRI, to fall between $278 million and $292 million. For the first half of 2026, collaboration revenue from YUPELRI totaled $38.4 million, based on $133.1 million in total sales.
From manilatimes.net
Why it matters
The deal structure allows Zymeworks to receive a 35% share of net U.S. profits from YUPELRI and royalties on net sales outside the United States. Zymeworks is leveraging acquired Irish tax attributes alongside its ongoing research and development activities in Ireland.
Mylan and Zymeworks are involved in a deal aimed at bolstering Zymeworks’ commercial portfolio, related to COPD therapy.
From manilatimes.net
Who's involved
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Revenue CommissionersSpeculative
The successful leveraging of favorable tax attributes could increase the tax base and revenue stream for the Revenue Commissioners.